Pharming Group N.V. - ADR (PHAR)
Pharming Group Q2 Earnings Call Highlights
Pharming Group NASDAQ: PHAR reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema therapy RUCONEST. The company reduced its full-year revenue outlook by $30 million but said it expects RUCONEST sales to stabilize and return to growth during the second half of 2026.
Pharming Group Q1 Earnings Call Highlights
Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company advanced regulatory and clinical milestones across its pipeline. Get Pharming Group alerts:Sign UpRUCONEST revenue declined as inventory dynamics played out CEO Fabrice Chouraqui said quarterly revenue fell primarily due to RUCONEST, a decline he said was “largely expected due to inventory drawdown at specialty pharmacy,” which the company previously discussed on its fourth-quarter 2025 call.
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Pharming Group: Crossing From Speculation To Profitability
Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, and generated $44M in operating cash flow, supporting financial independence. Key near-term catalysts include FDA approval for Joenja's pediatric label and pivotal data from leniolisib and KL1333 clinical programs.
Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript
Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript
Wall Street Analysts Believe Pharming Group (PHAR) Could Rally 81.71%: Here's is How to Trade
The mean of analysts' price targets for Pharming Group (PHAR) points to an 81.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy?
Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 145.8% in Pharming Group (PHAR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR ) Q2 2025 Earnings Conference Call July 31, 2025 7:30 AM ET Executives Anurag Relan – Chief Medical Officer Fabrice Chouraqui – CEO & Executive Director Stephen Toor – Chief Commercial Officer & GM Americas Analysts Benjamin Jackson - Jefferies Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Simon Scholes - First Berlin Equity Research GmbH Sushila Hernandez - Kempen & Co Fabrice Chouraqui Good morning or good afternoon, everyone, and welcome to our Q2 2025 earnings call.
Best Momentum Stocks to Buy for July 17th
PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.
Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR ) Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ET Company Participants Fabrice Chouraqui – CEO Stephen Toor – CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Joe Pantginis - H.C.
